AWL Agri Business Reports 26% Revenue Growth to INR 22,202 Crore in Q2 FY27 with 11% Rise in Operating EBITDA
Food & FMCG segment revenue increases 32% YoY to INR 2,216 crore; H1 FY27 revenue rises 22% to INR 42,250 crore
AWL Agri Business Ltd. announced strong financial results for Q2 and H1 FY27, reporting a 26% year-on-year revenue increase to INR 22,202 crore in Q2 and 11% growth in normalized operating EBITDA to INR 623 crore. Revenue growth was driven by a 32% rise in the Food & FMCG segment, crossing INR 2,200 crore for the quarter, alongside 14% volume growth overall. The company also reported 22% revenue growth in H1 FY27 to INR 42,250 crore and a 25% increase in operating EBITDA to INR 1,347 crore.
AWL Agri Business Ltd.
General / Other
AWL Agri Business Ltd. reported consolidated revenue of INR 22,202 crore for the quarter ended September 30, 2026, representing a 26% year-on-year increase driven by 14% volume growth. Normalized operating EBITDA rose 11% to INR 623 crore, supported by strong performance in the Food & FMCG segment, which grew 32% in revenue.
The Food & FMCG segment recorded revenues of INR 2,216 crore for Q2 FY27, growing 32% YoY with an EBITDA margin of 3.2%, aligning with company guidance. Key products such as Basmati Rice and Fortune Pulses showed double-digit growth, while the Health & Convenience portfolio surpassed INR 1,400 crore in last twelve months revenues.
The Edible Oils segment achieved 5% volume growth year-on-year with EBITDA margins around INR 4,100 per metric ton. The Industry Essentials segment also delivered 26% volume growth, boosted by Oleochemicals & Specialty Chemicals that contributed approximately 45% of segment revenue and grew over 25% YoY.
For the half year ended September 30, 2026, AWL’s consolidated revenue increased 22% to INR 42,250 crore with underlying volume growth of 11%. Normalized operating EBITDA rose 25% to INR 1,347 crore. Profit before tax including joint ventures grew 27% YoY to INR 822 crore, and profit after tax increased 22% YoY to INR 591 crore.
Highlights
- Consolidated Q2 FY27 revenue reached INR 22,202 crore, a 26% increase YoY.
- Normalized operating EBITDA grew 11% YoY to INR 623 crore in Q2 FY27.
- Food & FMCG revenues up 32% YoY to INR 2,216 crore with 3.2% EBITDA margin.
- Q2 underlying volume growth of 14% across consolidated business.
- H1 FY27 revenue increased 22% YoY to INR 42,250 crore, with 25% growth in EBITDA.
- Profit after tax for H1 FY27 stood at INR 591 crore, up 22% YoY.
Key Data Snapshot
What happened
- AWL Agri Business announced its consolidated and standalone unaudited financial results for the quarter and half year ended September 30, 2026.
- The company reported consolidated revenue of INR 22,202 crore for Q2 FY27, up 26% year-on-year, with volume growth of 14%.
- Normalized operating EBITDA for Q2 FY27 rose 11% to INR 623 crore.
- Profit after tax for Q2 FY27 was INR 239 crore, slightly down from INR 245 crore in the previous year quarter due to tax regulations affecting the Bangladesh subsidiary.
- H1 FY27 consolidated revenue increased 22% to INR 42,250 crore, with operating EBITDA up 25% to INR 1,347 crore.
Key details
- Food & FMCG segment revenue crossed INR 2,200 crore, growing 32% YoY, maintaining EBITDA margin at 3.2%.
- Rice and Wheat Flour categories showed double-digit revenue growth; Basmati Rice and Kohinoor brands gained market share.
- Fortune Pulses grew over 40% YoY, with quarterly revenues exceeding INR 100 crore.
- Health & Convenience portfolio’s last twelve months revenues surpassed INR 1,400 crore.
- Edible Oils segment grew volume by 5% YoY with EBITDA around INR 4,100 per metric ton.
- Industry Essentials segment volume grew 26% YoY; specialty chemicals contributed 45% of segment revenue and grew over 25% YoY.
Background and context
- AWL Agri Business Ltd. was formerly known as Adani Wilmar Ltd.
- The company focuses on building one of India’s largest food platforms anchored in Daily Essentials and Centre-of-the-Plate categories.
- The strategy includes accelerating growth in packaged foods, expanding premium, health, and convenience offerings, and enhancing profitability through scale and efficiencies.
- AWL continues to invest in branded portfolio strengthening, product innovation, and expanding distribution networks.
Next milestones
- AWL plans to continue expanding the premium, health-oriented, and convenience-led food categories.
- Further scaling of value-added Oleochemicals and Specialty Chemicals portfolio leveraging global R&D capabilities.
- Strengthening market leadership in Edible Oils with focus on branded and premium products.
- Expanding General Trade distribution network to increase retail reach.
Highlights
- Consolidated Q2 FY27 revenue reached INR 22,202 crore, a 26% increase YoY.
- Normalized operating EBITDA grew 11% YoY to INR 623 crore in Q2 FY27.
- Food & FMCG revenues up 32% YoY to INR 2,216 crore with 3.2% EBITDA margin.
- Q2 underlying volume growth of 14% across consolidated business.
- H1 FY27 revenue increased 22% YoY to INR 42,250 crore, with 25% growth in EBITDA.
- Profit after tax for H1 FY27 stood at INR 591 crore, up 22% YoY.
Disclosures
- Listing Obligations and Disclosure Requirements (LODR) Regulations
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Park Medi World reallocates Rs 648.32 million IPO proceeds for The Medicity Hospital acquisition, confirms CRISIL monitoring report
Park Medi World Limited announced that, as per the Monitoring Agency Report by CRISIL Ratings for the quarter ended September 30, 2026, the company utilized IPO proceeds with certain deviations from the original objects approved by shareholders. A key reallocation involved Rs 648.32 million directed towards funding capital expenditure for the acquisition of The Medicity Hospital, Rudrapur.
Read Full StoryViyash Scientific Limited Reports 17.8% Revenue Growth and 49.4% Profit Rise for H1 FY27 with Strategic Expansion Moves
Viyash Scientific Limited posted a 17.8% increase in revenue to ₹19,343 million and a 49.4% rise in profit after tax to ₹1,639 million for the half year ended September 30, 2026, reflecting growth across its integrated pharmaceutical operations.
Read Full StoryJubilant Pharmova Delivers 21% Revenue Growth in Q2 FY27 with Rs. 800 Crore Debt Refinancing
Jubilant Pharmova Limited posted a 21% year-on-year revenue increase to Rs. 2,370 crore in Q2 FY27, driven by broad-based business expansion and strategic agreements, alongside raising Rs. 800 crore via Non-convertible debentures to refinance debt and fund investments.
Read Full Story